770 related articles for article (PubMed ID: 28122866)
21. Proteasome Inhibition Overcomes ALK-TKI Resistance in
Tanimoto A; Matsumoto S; Takeuchi S; Arai S; Fukuda K; Nishiyama A; Yoh K; Ikeda T; Furuya N; Nishino K; Ohe Y; Goto K; Yano S
Clin Cancer Res; 2021 Mar; 27(5):1410-1420. PubMed ID: 33310890
[TBL] [Abstract][Full Text] [Related]
22. Structure and energy based quantitative missense variant effect analysis provides insights into drug resistance mechanisms of anaplastic lymphoma kinase mutations.
Li J; Huang Y; Wu M; Wu C; Li X; Bao J
Sci Rep; 2018 Jul; 8(1):10664. PubMed ID: 30006516
[TBL] [Abstract][Full Text] [Related]
23. Changing ALK-TKI-Resistance Mechanisms in Rebiopsies of
Urbanska EM; Sørensen JB; Melchior LC; Costa JC; Santoni-Rugiu E
Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32325863
[No Abstract] [Full Text] [Related]
24. [Current Status for Anaplastic Lymphoma Kinase in Non-small Cell Lung Cancer].
Song P; Zhang L; Shang C
Zhongguo Fei Ai Za Zhi; 2018 Sep; 21(9):703-711. PubMed ID: 30201071
[TBL] [Abstract][Full Text] [Related]
25. Management of Resistance to First-Line Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor Therapy.
Peters S; Zimmermann S
Curr Treat Options Oncol; 2018 May; 19(7):37. PubMed ID: 29808239
[TBL] [Abstract][Full Text] [Related]
26. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers.
Katayama R; Shaw AT; Khan TM; Mino-Kenudson M; Solomon BJ; Halmos B; Jessop NA; Wain JC; Yeo AT; Benes C; Drew L; Saeh JC; Crosby K; Sequist LV; Iafrate AJ; Engelman JA
Sci Transl Med; 2012 Feb; 4(120):120ra17. PubMed ID: 22277784
[TBL] [Abstract][Full Text] [Related]
27. The battle against ALK resistance: successes and setbacks.
Voena C; Chiarle R
Expert Opin Investig Drugs; 2012 Dec; 21(12):1751-4. PubMed ID: 22920921
[TBL] [Abstract][Full Text] [Related]
28. Precision medicine in ALK rearranged NSCLC: A rapidly evolving scenario.
Addeo A; Tabbò F; Robinson T; Buffoni L; Novello S
Crit Rev Oncol Hematol; 2018 Feb; 122():150-156. PubMed ID: 29458783
[TBL] [Abstract][Full Text] [Related]
29. Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors.
Lovly CM; Heuckmann JM; de Stanchina E; Chen H; Thomas RK; Liang C; Pao W
Cancer Res; 2011 Jul; 71(14):4920-31. PubMed ID: 21613408
[TBL] [Abstract][Full Text] [Related]
30. Relevance of Detection of Mechanisms of Resistance to ALK Inhibitors in ALK-Rearranged NSCLC in Routine Practice.
Jamme P; Descarpentries C; Gervais R; Dansin E; Wislez M; Grégoire V; Richard N; Baldacci S; Rabbe N; Kyheng M; Kherrouche Z; Escande F; Copin MC; Cortot AB
Clin Lung Cancer; 2019 Jul; 20(4):297-304.e1. PubMed ID: 31147208
[TBL] [Abstract][Full Text] [Related]
31. Histological transformation of ALK rearranged adenocarcinoma into small cell lung cancer: A new mechanism of resistance to ALK inhibitors.
Levacq D; D'Haene N; de Wind R; Remmelink M; Berghmans T
Lung Cancer; 2016 Dec; 102():38-41. PubMed ID: 27987586
[TBL] [Abstract][Full Text] [Related]
32. Anaplastic Lymphoma Kinase Fusion: A Review of Therapeutic Drugs and Treatment Strategies.
Makimoto G; Ohashi K; Maeda Y; Kiura K
Acta Med Okayama; 2020 Oct; 74(5):371-379. PubMed ID: 33106692
[TBL] [Abstract][Full Text] [Related]
33. New strategies for treatment of ALK-rearranged non-small cell lung cancers.
Sasaki T; Jänne PA
Clin Cancer Res; 2011 Dec; 17(23):7213-8. PubMed ID: 22010214
[TBL] [Abstract][Full Text] [Related]
34. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.
Doebele RC; Pilling AB; Aisner DL; Kutateladze TG; Le AT; Weickhardt AJ; Kondo KL; Linderman DJ; Heasley LE; Franklin WA; Varella-Garcia M; Camidge DR
Clin Cancer Res; 2012 Mar; 18(5):1472-82. PubMed ID: 22235099
[TBL] [Abstract][Full Text] [Related]
35. The anaplastic lymphoma kinase as an oncogene in solid tumors.
Voena C; Peola S; Chiarle R
Front Biosci (Schol Ed); 2015 Jun; 7(2):269-82. PubMed ID: 25961702
[TBL] [Abstract][Full Text] [Related]
36. Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer.
Recondo G; Mezquita L; Facchinetti F; Planchard D; Gazzah A; Bigot L; Rizvi AZ; Frias RL; Thiery JP; Scoazec JY; Sourisseau T; Howarth K; Deas O; Samofalova D; Galissant J; Tesson P; Braye F; Naltet C; Lavaud P; Mahjoubi L; Abou Lovergne A; Vassal G; Bahleda R; Hollebecque A; Nicotra C; Ngo-Camus M; Michiels S; Lacroix L; Richon C; Auger N; De Baere T; Tselikas L; Solary E; Angevin E; Eggermont AM; Andre F; Massard C; Olaussen KA; Soria JC; Besse B; Friboulet L
Clin Cancer Res; 2020 Jan; 26(1):242-255. PubMed ID: 31585938
[TBL] [Abstract][Full Text] [Related]
37. Serial liquid biopsies for detection of treatment failure and profiling of resistance mechanisms in
Dietz S; Christopoulos P; Gu L; Volckmar AL; Endris V; Yuan Z; Ogrodnik SJ; Zemojtel T; Heussel CP; Schneider MA; Meister M; Muley T; Reck M; Schlesner M; Thomas M; Stenzinger A; Sültmann H
Cold Spring Harb Mol Case Stud; 2019 Dec; 5(6):. PubMed ID: 31753813
[TBL] [Abstract][Full Text] [Related]
38. Treatment of advanced ALK-rearranged NSCLC following second-generation ALK-TKI failure.
Fukuda A; Yoshida T
Expert Rev Anticancer Ther; 2023; 23(11):1157-1167. PubMed ID: 37772744
[TBL] [Abstract][Full Text] [Related]
39. Treating patients with ALK-rearranged non-small-cell lung cancer: mechanisms of resistance and strategies to overcome it.
Drizou M; Kotteas EA; Syrigos N
Clin Transl Oncol; 2017 Jun; 19(6):658-666. PubMed ID: 28054318
[TBL] [Abstract][Full Text] [Related]
40. Detection of anaplastic lymphoma kinase (ALK) gene rearrangement in non-small cell lung cancer and related issues in ALK inhibitor therapy: a literature review.
Yi ES; Chung JH; Kulig K; Kerr KM
Mol Diagn Ther; 2012 Jun; 16(3):143-50. PubMed ID: 22506598
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
